Result of AGM

RNS Number : 6478E
Dechra Pharmaceuticals PLC
19 October 2018
 

 

 

Date: 19 October 2018

 

Dechra® Pharmaceuticals PLC

Results of Annual General Meeting (AGM)

 

 

AGM Meeting Date: 10.30 am on 19 October 2018

 

Issued Share Capital at meeting date: 102,336,635

 

Number of shareholders in attendance: 9

 

All resolutions were passed on a show of hands.

 

Details of the proxy voting instructions lodged prior to the AGM are set out below:

 

Resolution (No. as noted on proxy form)

 

Total For (1)

Total Against

Withheld (2)


No. of votes

% of vote

No. of votes

% of vote

No. of votes

Resolution 1:

To receive the accounts, the Strategic Report, the Directors' Report and the Auditor's Report

 

73,623,740

95.88

3,162,913

4.12

377,261

Resolution 2:

To approve the Directors' Remuneration Report

 

76,045,670

98.58

1,092,914

1.42

25,330

Resolution 3:

To declare a final dividend

 

77,160,743

100.00

3,172

0.00

0

Resolution 4:

To re-elect William Anthony Rice

 

71,931,907

93.24

5,212,000

6.76

20,007

Resolution 5:

To re-elect Ian Page

 

76,265,790

98.84

898,039

1.16

86

Resolution 6:

To re-elect Richard Cotton

 

76,089,363

98.61

1,074,466

1.39

86

Resolution 7:

To re-elect Anthony Griffin

 

76,248,926

98.81

914,902

1.19

86

Resolution 8:

To re-elect Julian Heslop

 

76,471,131

99.10

692,698

0.90

86

Resolution 9:

To re-elect Ishbel Macpherson

 

76,540,810

99.22

603,098

0.78

20,007

Resolution 10:

To re-elect Lawson Macartney

 

76,643,113

99.33

520,716

0.67

86

Resolution 11:

To re-appoint PricewaterhouseCoopers as external auditor of the Company

 

76,021,787

98.52

1,141,654

1.48

473

Resolution 12:

To authorise the Audit Committee to determine the remuneration of the external auditor

 

76,655,223

99.34

508,169

0.66

523

Resolution 13:

To authorise the Directors to allot shares to specific limits

 

75,498,018

97.84

1,664,325

2.16

1,572

Resolution 14:

To disapply the pre-emption rights

 

73,792,966

95.63

3,369,827

4.37

1,122

Resolution 15:

To disapply additional
pre-emption rights

 

73,637,601

95.43

3,523,885

4.57

2,428

Resolution 16:

To authorise the Company to purchase its own shares

 

76,382,960

99.00

773,210

1.00

7,744

Resolution 17:

To call general meetings (other than an AGM) on not less than 14 clear days' notice

 

75,446,021

97.77

1,717,894

2.23

0

Resolution 18:

(a)  To approve the rules of the Dechra Global Save As You Earn Scheme 2018 (2018 SAYE Plan); and

(b)  To authorise the Directors to adopt further plans based on the 2018 SAYE Plan

 

76,738,556

99.45

423,701

0.55

1,658

 

 

Notes

1.   Includes discretionary votes.

2.   A "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of votes "For" and "Against" a resolution.

3.   Resolutions 1 to 13 and Resolution 18 were ordinary resolutions, requiring more than 50% of shareholder votes to be "For" the resolutions.

4.   Resolutions 14 to 17 were special resolutions, requiring more than 75% of shareholder votes to be "For" the resolutions.

5.   Votes tendered in respect of 77,163,915 shares representing 75.40% of the issued share capital.

 

In accordance with Listing Rule 9.6.2R, a copy of the resolutions passed as special business at the AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm.

 

For further information, please contact:

 

Melanie Hall, Company Secretary                           

Telephone number: 01606 814730

 

 

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information, please visit: www.dechra.com.

 

Trademarks

Trademarks appear throughout this document in italics.  Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGEAAENFDSPFFF
UK 100

Latest directors dealings